Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation

October 2019

Zelnorm (tegaserod) will be back on the market to treat irritable bowel syndrome with constipation (IBS-C) in women.

It was first approved in 2002...then taken off the market in 2007 due to reports of MI, stroke, and unstable angina.

Since then, it's been available on a case-by-case basis from various manufacturers.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

E-Cigarettes Emphasize Risks of Vaping and Help Kids and Teens Stop
Influenza Share the Latest Advice About 2019-2020 Influenza Immunizations
Practice Demystify the Ins and Outs of Compression Stockings
Anticoagulants Be Prepared to Manage Direct Oral Anticoagulants Around Surgery
Pediatrics Weigh Options for Managing Type 2 Diabetes in Kids
Contraceptives Don't Jump to the New Progestin-Only Oral Contraceptive, Slynd (Drospirenone)
Immunosuppressives Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)
Vaccines Know When to Discuss HPV Vaccination With Adults Over Age 26
Antibiotics Save the Antibiotic Xenleta as a Last Resort
Medicare Be Familiar With Changes Coming to Medicare Part D in 2020
IBS Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation
Fungal Infections Avoid Empiric Fluconazole for Candida auris